These results differ from those observed in a cohort of 249 advanced NSCLC, renal cell and urothelial carcinoma patients, in which 28% of patients received antibiotics within 2 months before or 1 month after the initiation of anti-PD-(L)1 blockade agents, for whom both PFS and OS were significantly shorter (34). The gene discussed is CD274; the disease is non-small cell lung carcinoma.